ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2019
Inhibition of growth and ochratoxin A production in Aspergillus species by fungi isolated from coffee beans.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 35 citations in OpenAlex.
- EndophyticMicrobiology spectrum · 2025Article
- Application and antagonistic mechanisms of atoxigenicApplied and environmental microbiology · 2024Review
- Reduction in Ochratoxin A Occurrence in Coffee: From Good Practices to Biocontrol Agents.Journal of fungi (Basel, Switzerland) · 2024Review
- Comprehensive Review of Aflatoxin and Ochratoxin A Dynamics: Emergence, Toxicological Impact, and Advanced Control Strategies.Foods (Basel, Switzerland) · 2024Review
- Microbial Diversity of Anaerobic-Fermented Coffee and Potential for Inhibiting Ochratoxin-ProducedFoods (Basel, Switzerland) · 2023Article
- Discovery of a NewJournal of fungi (Basel, Switzerland) · 2023Article
- Efficient Biodegradation of Patulin byFoods (Basel, Switzerland) · 2023Article
- Single-Molecule Real-Time Sequencing to Explore the Mycobiome Diversity in Malt.Microbiology spectrum · 2022Article
- Characterization of Ugandan EndemicToxins · 2022Article
- Comprehensive Review of Fungi on Coffee.Pathogens (Basel, Switzerland) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ochratoxin A (OTA) is a mycotoxin found in several agricultural commodities. Produced by Aspergillus spp., it is nephrotoxic and hepatotoxic and can be carcinogenic. Preventive measures are preventing fungal growth and OTA production. In this study, fungal strains (Rhizopus oryzae, Lichtheimia ramosa, Aspergillus westerdijkiae, Aspergillus niger, Aspergillus tamarii, Aspergillus sp., and Aspergillus fumigatus) isolated from coffee beans were identified for their abilities to inhibit the growth of Aspergillus ochraceus, Aspergillus westerdijkiae, Aspergillus carbonarius, and Aspergillus niger, and OTA production. All fungi strains tested were able to inhibit growth of the four Aspergillus species and OTA production, where A. niger showed the best results in both tests. L. ramosa showed the lowest growth-reducing potential, while the other fungal strains had a growth-reducing potential higher than 70% against all Aspergillus species tested. Regarding OTA production, L. ramosa and Aspergillus sp. completely inhibited the mycotoxin production by A. ochraceus and non-toxigenic strain A. niger completely inhibited OTA production by A. niger. Our findings indicate that the strains tested can be used as an alternative means to control growth of OTA-producing fungi and production of the mycotoxin in coffee beans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.